Overview of the NOD/SCID Xenograft Model
NOD/SCID mice are a widely used immunodeficient model for human tumor xenografting, offering a highly permissive in vivo system for evaluating cancer cell proliferation, metastasis, and response to therapeutics. These mice carry a double mutation: the non-obese diabetic (NOD) background impairs innate immune function, while the severe combined immunodeficiency (SCID) mutation disrupts B-cell and T-cell development. The resulting immunological profile prevents graft rejection of human cells, making NOD/SCID mice an ideal host for patient-derived xenografts (PDX) and cultured human tumor lines.
Scientific Applications
This xenograft model enables translational oncology studies under conditions that closely replicate the human tumor microenvironment. NOD/SCID mice are routinely used in the development of personalized medicine approaches, including efficacy testing of small molecules, RNA-based therapeutics, immunomodulators, and gene-editing strategies. Due to their deficient adaptive immunity, these mice allow for extended engraftment of human cells without immune clearance, supporting tumor progression studies, angiogenesis evaluation, and tumor-host interaction assays.
Study Design and Tumor Implantation Methods
Tumor xenografts are established using subcutaneous, orthotopic, or intravenous injection methods depending on the cancer type and research goals. Subcutaneous implantation provides easy monitoring of tumor volume and is optimal for dose-response and tumor regression studies. Orthotopic implantation places tumor cells within their tissue of origin, supporting accurate modeling of local invasion and organ-specific tumor behavior. Intravenous injection of cancer cells is often used for experimental metastasis studies, particularly in hematologic malignancies or highly aggressive carcinomas.
Advantages of the NOD/SCID Model
NOD/SCID mice offer superior human cell engraftment efficiency compared to other immunodeficient strains. They lack both natural killer (NK) cell activity and complement activation pathways, which are major barriers to stable xenograft establishment in less immunocompromised hosts. Their lifespan is adequate for long-term treatment schedules, survival endpoints, and tumor latency studies. Tumors in this model show consistent take rates and reproducible growth kinetics, making it well-suited for high-confidence preclinical screening.
Pharmacology and Toxicology Integration
Drug candidates tested in NOD/SCID xenografts can be assessed for antitumor activity alongside toxicology profiling. Tumor-bearing animals are monitored for systemic toxicity, weight loss, organ-specific adverse effects, and hematologic parameters during and after compound administration. This dual readout—efficacy and safety—streamlines IND-enabling data collection and improves early detection of dose-limiting toxicities in a clinically relevant model.
Altogen Labs Xenograft Services
Altogen Labs provides fully integrated xenograft services utilizing NOD/SCID mice, including tumor cell preparation, implantation, dosing, monitoring, and endpoint analysis. Histopathology, immunohistochemistry, and molecular profiling of tumor tissue are available to complement efficacy studies. Custom study design is available for solid tumors, hematologic malignancies, or PDX models, with full regulatory support for GLP-compliant reporting and IND documentation.